Egreat Biotech Private Limited
Founded in 2021 and headquartered in Bihar, India.
2021 | Patna, Bihar (India) | Active
Egreat Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
About Egreat Biotech
Egreat Biotech Private Limited (EBPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 March 2021 (Three years and 11 months 16 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Abhishek Kumar, Nitish Kumar, Rahul Kumar, and One other member serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230BR2021PTC051073
- Company No.
051073
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2021
- Date of AGM
02 Nov 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Chemicals
Pharmaceuticals
Who are the key members and board of directors at Egreat Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Anand  | Managing Director | 12-Mar-2021 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abhishek Kumar | Additional Director | 15-Sep-2021 | Current |
| Nitish Kumar | Additional Director | 15-Sep-2021 | Current |
| Rahul Kumar | Director | 12-Mar-2021 | Current |
Financial Performance of Egreat Biotech.
Enhance accessibility to Egreat Biotech's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Egreat Biotech?
Unlock access to Egreat Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Egreat Biotech?
Egreat Biotech has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Egreat Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Egreat Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.